Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | SMO | Q99835 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31679062 | 1.00 | TRPV1 (0.56) | TRPV1OPRD1OPRK1OPRM1PDGFRB | |
| SCHEMBL17310439 | 0.90 | TRPV1 (0.47) | TRPV1PDGFRBKDM4EMAPTFAAH | |
| SCHEMBL31679064 | 0.90 | TRPV1 (0.58) | TRPV1ALDH1A1MAPTFAAH | |
| SCHEMBL2724882 | 0.90 | TRPV1 (0.58) | TRPV1ALDH1A1MAPTFAAH | |
| SCHEMBL27666943 | 0.89 | TRPV1 (0.57) | TRPV1ALDH1A1KDM4EMAPT | |
| SCHEMBL31679069 | 0.89 | TRPV1 (0.59) | TRPV1ALDH1A1KDM4EMAPTGAA | |
| SCHEMBL2725244 | 0.89 | TRPV1 (0.59) | TRPV1ALDH1A1KDM4EMAPTGAA | |
| SCHEMBL2724621 | 0.87 | TRPV1 (0.62) | TRPV1ALDH1A1KDM4EMAPT | |
| SCHEMBL19946397 | 0.87 | TRPV1 (0.56) | TRPV1ALDH1A1KDM4EMAPTFAAH | |
| SCHEMBL2723775 | 0.86 | TRPV1 (0.55) | TRPV1PDGFRBKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240189303-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY | UNIVERSITY OF HAWAII | 2024-06-13 | — | — | US | claimed |
| EP-3393462-B1 | COMPOSITIONS AND METHODS FOR TREATMENT, AMELIORATION, AND PREVENTION OF ANESTHESIA-INDUCED HYPOTHERMIA | UNIV ARIZONA (US) | 2023-02-01 | — | — | EP | claimed |
| US-20210069184-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY | UNIV HAWAII (US) | 2021-03-11 | — | — | US | claimed |
| US-20190192508-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY | UNIV HAWAII (US) | 2019-06-27 | — | — | US | claimed |
| US-20190008865-A1 | COMPOSITIONS AND METHODS FOR TREATMENT, AMELIORATION, AND PREVENTION OF ANESTHESIA-INDUCED HYPOTHERMIA | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2019-01-10 | — | — | US | claimed |
| US-10137123-B2 | Methods and compositions for prevention and treatment of cardiac hypertrophy | UNIVERSITY OF HAWAII (US) | 2018-11-27 | — | — | US | claimed |
| EP-3393462-A1 | COMPOSITIONS AND METHODS FOR TREATMENT, AMELIORATION, AND PREVENTION OF ANESTHESIA-INDUCED HYPOTHERMIA | Arizona Board of Regents on behalf of the University of Arizona (US) | 2018-10-31 | — | — | EP | claimed |
| US-20170231982-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY | UNIVERSITY OF HAWAII | 2017-08-17 | — | — | US | claimed |
| WO-2017112693-A1 | COMPOSITIONS AND METHODS FOR TREATMENT, AMELIORATION, AND PREVENTION OF ANESTHESIA-INDUCED HYPOTHERMIA | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2017-06-29 | — | — | WO | claimed |
| US-20150352105-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-12-10 | — | — | US | claimed |
| US-9084786-B2 | Methods and compositions for prevention and treatmentof cardiac hypertrophy | UNIVERSITY OF HAWAII (US) | 2015-07-21 | — | — | US | claimed |
| US-20130274271-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENTOF CARDIAC HYPERTROPHY | UNIVERSITY OF HAWAII (US) | 2013-10-17 | — | — | US | claimed |
| EP-2635281-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY | University Of Hawaii (US) | 2013-09-11 | — | — | EP | claimed |
| WO-2012061505-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY | UNIVERSITY OF HAWAII (US) | 2012-05-10 | — | — | WO | claimed |
| US-20070135423-A1 | E-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide derivatives and related compounds which modulate the function of the vanilloid-1 receptor (vr1) for the treatment of pain | MERCK SHARP & DOHME LTD. (GB) | 2007-06-14 | — | — | US | claimed |
| JP-2007509915-A | — | — | 2007-04-19 | — | — | JP | claimed |
| CN-1874775-A | 4-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide derivatives and related compounds which modulate the function of the vanilloid-1 receptor (VR1) for the treatment of pain | MERCK SHARP & DOHME (GB) | 2006-12-06 | — | — | CN | claimed |
| EP-1682141-A1 | 4-FLUORO-4-(PYRIDIN-2-YL)-PIPERIDINE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) FOR THE TREATMENT OF PAIN | MERCK SHARP & DOHME LTD. (GB) | 2006-07-26 | — | — | EP | claimed |
| WO-2005051390-A1 | E-FLUORO-4-(PYRIDIN-2-YL)-PIPERIDINE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) FOR THE TREATMENT OF PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2005-06-09 | — | — | WO | claimed |
| US-12186314-B2 | Compositions and methods for treatment, amelioration, and prevention of anesthesia-induced hypothermia | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240189303-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY | UNIVERSITY OF HAWAII | 2024-06-13 | — | — | US | disclosed |
| EP-3348267-B1 | TRPV1 INHIBITOR FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY | UNIV HAWAII (US) | 2024-01-10 | — | — | EP | disclosed |
| EP-3393462-B1 | COMPOSITIONS AND METHODS FOR TREATMENT, AMELIORATION, AND PREVENTION OF ANESTHESIA-INDUCED HYPOTHERMIA | UNIV ARIZONA (US) | 2023-02-01 | — | — | EP | disclosed |
| US-20190008865-A1 | COMPOSITIONS AND METHODS FOR TREATMENT, AMELIORATION, AND PREVENTION OF ANESTHESIA-INDUCED HYPOTHERMIA | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2019-01-10 | — | — | US | disclosed |
| EP-3393462-A1 | COMPOSITIONS AND METHODS FOR TREATMENT, AMELIORATION, AND PREVENTION OF ANESTHESIA-INDUCED HYPOTHERMIA | Arizona Board of Regents on behalf of the University of Arizona (US) | 2018-10-31 | — | — | EP | disclosed |
| EP-3348267-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY | University Of Hawaii (US) | 2018-07-18 | — | — | EP | disclosed |
| EP-2635281-B1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY | UNIV HAWAII (US) | 2018-03-14 | — | — | EP | disclosed |
| WO-2017112693-A1 | COMPOSITIONS AND METHODS FOR TREATMENT, AMELIORATION, AND PREVENTION OF ANESTHESIA-INDUCED HYPOTHERMIA | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2017-06-29 | — | — | WO | disclosed |
| US-20070135423-A1 | E-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide derivatives and related compounds which modulate the function of the vanilloid-1 receptor (vr1) for the treatment of pain | MERCK SHARP & DOHME LTD. (GB) | 2007-06-14 | — | — | US | disclosed |
| CN-1874775-A | 4-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide derivatives and related compounds which modulate the function of the vanilloid-1 receptor (VR1) for the treatment of pain | MERCK SHARP & DOHME (GB) | 2006-12-06 | — | — | CN | disclosed |
| EP-1682141-A1 | 4-FLUORO-4-(PYRIDIN-2-YL)-PIPERIDINE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) FOR THE TREATMENT OF PAIN | MERCK SHARP & DOHME LTD. (GB) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005051390-A1 | E-FLUORO-4-(PYRIDIN-2-YL)-PIPERIDINE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) FOR THE TREATMENT OF PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051390-A1 | E-FLUORO-4-(PYRIDIN-2-YL)-PIPERIDINE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) FOR THE TREATMENT OF PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135423-A1 | E-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide derivatives and related compounds which modulate the function of the vanilloid-1 receptor (vr1) for the treatment of pain | OPRL1, HVCN1, TRPV1 | TRPV1 3/4885OPRD1 4/4885OPRK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.